Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval

Stock Track08-07

Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.

The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.

The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151684334?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151684334","market":"sg","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.</p><p>The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.</p><p>The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.28% Intraday as First mRNA Flu Vaccine Wins FDA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 22:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.</p><p>The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.</p><p>The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1151684334","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151684334","pubTimestamp":1786113661,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.The rally followed the company's announcement that its seasonal influenza...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"股票追踪|Moderna盘中飙升5.28%，首个mRNA流感疫苗获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) shares surged 5.28% intraday, driven by a major regulatory milestone for the company's vaccine portfolio.The rally followed the company's announcement that its seasonal influenza vaccine, mFLUSIVA, has officially received U.S. Food and Drug Administration (FDA) approval. This marks the first mRNA-based vaccine to enter the flu market and represents Moderna's fourth FDA-cleared product in the United States. The approval covers use in adults aged 50 and above, with the vaccine expected to become available for the 2026-2027 respiratory virus season.The clearance serves as a significant achievement for Moderna, coming after a period of rare public disagreement with FDA regulators. The vaccine is also currently under regulatory review in Australia, Canada, and Europe, suggesting potential for further upside from global commercialization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151684334","isCrawlerRequest":true}